Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x100px

Document › Details

Abivax S.A.. (3/14/19). "Press Release: Abivax 2018 Financial Results and Operations Update". Paris.

	Organisation	Abivax S.A. (Euronext Paris: ABVX)
	Group	Abivax (Group)
	Organisation 2	Evotec AG (FSE: EVT, TecDAX)
	Today	Evotec SE (FSE: EVT, MDA X/TecDAX, Nasdaq: EVO)
	Group	Evotec (Group)
	Product	obefazimod (ABX464)
	Product 2	ABX196 (Abivax)
	Person	Ehrlich, Hartmut J. (Abivax 201410 CEO before Baxter BioScience 200712 VP Global RnD)
	Person 2	Blondel, Didier (Abivax 201701– CFO before Sanofi Pasteur MSD + Sanofi)

Original document
accessed by [iito] on 2019-03-16

Record changed: 2023-06-05

Picture EBD Group BIO-Europe 2024 Stockholm from 14 Sep 650x200px

More documents for Abivax (Group)

[1] Abivax S.A.. (10/24/23). "Press Release: Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market". Paris....
[2] Abivax S.A.. (10/20/23). "Press Release: Abivax Announces the Pricing of Its Initial Public Offering on the Nasdaq Global Market". Paris....
[3] Abivax S.A.. (9/29/23). "Press Release: Abivax Files Registration Statement for Proposed Initial Public Offering in the United States". Paris....
[4] Abivax S.A.. (8/23/23). "Press Release: Abivax Appoints Patrick Malloy as Senior Vice President Investor Relations". Paris....
[5] Abivax S.A.. (8/21/23). "Press Release: Abivax Secures Up to EUR 150M from Two Structured Debt Financing Transactions". Paris....
[6] Abivax S.A.. (7/11/23). "Press Release: Abivax Announces the Appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors". Paris....
[7] Abivax S.A.. (9/2/22). "Press Release: Abivax Announces Successful Oversubscribed EUR 49.2M Cross-over Financing with Top-tier US and European Biotech Investors [not for US]". Paris....
[8] Abivax S.A.. (7/23/21). "Press Release: Abivax Announces the Pricing of Its Oversubscribed Capital Increase of EUR 60M and Convertible Bonds of EUR 25M, Totaling EUR 85M New Financing". Paris....
[9] Abivax S.A.. (6/23/21). "Press Release: Abivax Reports Excellent Phase 2a Clinical Safety and Efficacy Results with 50mg ABX464 in Rheumatoid Arthritis". Paris....
[10] Abivax S.A.. (3/11/19). "Press Release: Abivax Presents Impressive New Phase 2a ABX464 Ulcerative Colitis 6-Months Maintenance Study Data in Oral Plenary Session at Annual Congress of European Crohn’s and Colitis Organisation (ECCO)". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]